High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease

Chest

Volumn 137, Issue 2, 2010, Pages 333-340

  Soriano, Joan B ^a,b   Rigo, Fernando ^c,d   Guerrero, Dolores ^a   Yañez, Aina ^a   Forteza, Josep F ^e   Frontera, Guillem ^d,e   Togores, Bernat ^a,b,e   Agustí, Alvar ^a,b,e,f  

^a CIMERA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Centro de Salud San Agustín   (Spain)

^d Primary Care Research RedIAPP   (Spain)

^e HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DYSPNEA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPIROMETRY;

EID: 76749135711     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-1264     Document Type: Article

References (26)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498-1504.
2. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397-412.
3. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523-532.
4. Buist AS, McBurnie MA, Vollmer WM, et al; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a populationbased prevalence study. Lancet. 2007;370(9589):741-750.
5. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291(21):2616-2622.
6. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2(1):8-11.
7. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128(4):2099-2107.
8. Hansell AL, Lam KA, Richardson S, Visick G, Soriano JB. Medical event profi ling of COPD patients. Pharmacoepidemiol Drug Saf. 2004;13(8):547-555.
9. Rodríguez-Roisin R, Soriano JB. Chronic obstructive pulmonary disease with lung cancer and/or cardiovascular disease. Proc Am Thorac Soc. 2008;5(8):842-847.
10. Rigo F, Frontera G, Llobera J, Rodríguez T, Borrás I, Fuentespina E. Prevalencia de factores de riesgo cardiovascular en las Islas Baleares (estudio CORSAIB). Rev Esp Cardiol. 2005;58(12):1411-1419.
11. Miller MR, Hankinson J, Brusasco V, et al ; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
12. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581-586.
13. Ferris BG. Epidemiology standardization project (American Thoracic Society). Am Rev Respir Dis. 1978;118(6 pt 2)(suppl 1):1-120.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
15. Rabe KF, Hurd S, Anzueto A, et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532-555.
16. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946.
17. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16(1):63-70.
18. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962-969.
19. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail. 2006;8(7):706-711.
20. Peña VS, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest. 2000;118(4):981-989.
21. Menezes AM, Perez-Padilla R, Jardim JR, et al; PLATINO Team. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005;366(9500):1875-1881.
22. Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008;63(5):402-407.
23. Cazzola M, MacNee W, Martinez FJ, et al; American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416-469.
24. Pérez-Padilla R, Vázquez-García JC, Márquez MN, Menezes AM; PLATINO Group. Spirometry quality-control strategies in a multinational study of the prevalence of chronic obstructive pulmonary disease. Respir Care. 2008;53(8):1019-1026.
25. Soriano JB, Zielinski J, Price D. Screening for and early detection of COPD: feasibility and impact. Lancet. 2009;374(9691):721-732.
26. Miettinen OS. Striving to deconfound the fundamentals of epidemiologic study design. J Clin Epidemiol. 1988;41(8):709-713.